Answers are grounded in this paper and cite their sources.
Real-world data demonstrate tafamidis reduces mortality in transthyretin amyloid cardiomyopathy, suggesting its clinical relevance.
In this real-world cohort, treatment with tafamidis 61 mg was effective and safe, being associated with significantly reduced all-cause and cardiovascular mortality across all disease stages. These findings extend clinical trial evidence into routine practice and highlight the value of specialized amyloidosis programs in optimizing outcomes for patients with ATTR-CM.
No takes yet. Share an insight, caveat, or question.
Carvalho et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: